Biotechnology

Adagene

Adagene Announces Strong Muzastotug Data and Partnership with InCyte for MSI-Colorectal Cancer

Adagene released FY2025 Annual Earnings on April 1 (EST), actual revenue USD 7.671 M (forecast USD 1.667 M), actual EPS USD -0.375 (forecast USD -0.505)

Adagene released FY2025 Q3 earnings on April 1 (EST), actual revenue USD 3.835 M (forecast USD 0), actual EPS USD -0.0439 (forecast USD -0.15)

Adagene released FY2025 9 Months Earnings on April 1, 2026 (EST), with actual revenue of USD 3.835 M and EPS of USD -0.3314

Adagene released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1437 (forecast USD -0.19)

Adagene released FY2025 Semi-Annual earnings on August 12 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2875 (forecast USD -0.32)

Adagene released FY2025 Q1 earnings on August 12 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1437 (forecast USD -0.17)

Tianyan Pharmaceuticals Attends Jefferies Global Healthcare Conference

Adagene released FY2024 9 Months Earnings on March 24 (EST), with actual revenue of 51.6 K USD and EPS of -0.5663 USD

Adagene released FY2024 annual earnings on March 24 (EST), actual revenue 103.2 K USD (forecast 9.5 M USD), actual EPS -0.7422 USD (forecast -2.105 USD)

Adagene released FY2024 Q4 earnings on March 24 (EST), actual revenue 51.6K USD, actual EPS -0.1788 USD

Adagene released FY2024 Q3 earnings on March 24 (EST) with actual revenue of 51.6 K USD and EPS of -0.1788 USD

Tianyan Pharmaceutical to Showcase Anti-CTLA-4 Safebody® ADG126 Poster at SITC Annual Meeting

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ADAG

IBBQ

SBIO

ARKG

Adagene's Chief Strategy Officer, Mickael Chane-Du, discussed the company's clinical strategy for its lead antibody program, ADG126, focusing on improving CTLA-4 inhibition. ADG126, a masked anti-CTLA-4 antibody, aims to enhance therapeutic efficacy in colorectal cancer, particularly in microsatellite-stable patients without liver metastases. The company is conducting a randomized Phase 2 trial to evaluate ADG126's effectiveness in combination with pembrolizumab, with results expected to guide future trials.

Market Beat

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares US Pharma

iShares Global Healthcare

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | ADAG Stock News

StockTitan

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | ADAG Stock News

Adagene Inc. (NASDAQ:ADAG) has received an average recommendation of "Buy" from five brokerages, with one sell rating, two buy ratings, and two strong buy ratings. The average 1-year price target is $8.00. Recent institutional investments include Fifth Lane Capital increasing its stake by 427.3%. Adagene's stock opened at $3.81, with a 1-year range of $1.30 to $4.75. The company specializes in antibody-based therapeutics for cancer and immune-related diseases, leveraging its proprietary Bihanc™ antibody platform.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts

ZEPP

BIDU

FINV

Zepp Health(ZEPP) rose 5.9%, with a trading turnover 1.1 Million USD, and a year-to-date fell 54.7%. China Yuchai(CYD) rose 3.78%, with a trading turnover 3.7 Million USD, and a year-to-date rose 20.7%. NIO Inc(NIO) fell 4.86%, with a trading turnover 437.9 Million USD, and a year-to-date rose 19%. Baidu(BIDU) fell 4.65%, with a trading turnover 370.0 Million USD, and a year-to-date fell 17.2%.

- The Nasdaq Composite Index rose by 0.83%, with a year-to-date decrease of 1.8%, while the S&P 500 gained 0.62% and is down 0.3% for the year, and the Dow Jones increased by 0.58% with a 0.3% year-to-date gain.  
- Zepp (ZEPP) experienced a 5.9% increase, totaling $1.111 million in trading volume, but has seen a 54.7% decline this year, whereas Yuchai International (CYD) rose 3.78%, with a trading volume of $3.738 million and a 20.7% year-to-date gain.  
- Nio (NIO) fell by 4.86% with $440 million in trading volume, up 19% this year, and Baidu (BIDU) dropped 4.65% with $370 million in trading volume and a year-to-date decline of 17.2%.

Top Gainers&Losers

Zepp Health

China Yuchai

DingDong

Accendra Health

GigaCloud Tech

NIO Inc

Baidu

So-Young

FinVolution

Top 5 CDRs Gainers/Losers (>100M) (4.9)

Adagene Inc. (NASDAQ:ADAG) has received FY2026 earnings estimates from HC Wainwright, predicting a loss of ($0.37) per share, compared to the consensus estimate of ($0.60). Future earnings estimates include ($0.44) for FY2027 and ($0.74) for FY2028. The stock has a current average rating of "Buy" with a target price of $8.00. Recent trading shows shares opened at $4.00, with a 12-month range of $1.30 to $4.75. Institutional investors hold 9.51% of the company, which specializes in antibody-based therapeutics for cancer.

Analysts Offer Predictions for Adagene FY2026 Earnings

FUTU

ACMR

HSAI

CNTB

CHSN

UXIN

ECARX(ECX) rose 14%, with a trading turnover 1.5 Million USD, and a year-to-date fell 33.7%. Futu(FUTU) rose 11.47%, with a trading turnover 543.3 Million USD, and a year-to-date fell 4.3%. Adagene(ADAG) fell 9.71%, with a trading turnover 3.9 Million USD, and a year-to-date rose 111.6%. Connect Biopharma(CNTB) fell 6.74%, with a trading turnover 1.3 Million USD, and a year-to-date fell 6.7%.

- The Nasdaq Composite Index increased by 2.8%, with a year-to-date decline of 2.6%.  
- The S&P 500 rose by 2.51%, down 0.9% for the year, while the Dow Jones gained 2.85% and is down 0.3% year-to-date.  
- ECARX surged 14% with a trading volume of $1.454 million, and Futu Holdings rose by 11.47% with $540 million in trades, whereas Tianyan Pharmaceuticals fell by 9.71% despite a 111.6% year-to-date increase.

ECARX

Futu

ACM Research

Hesai

Connect Biopharma

Chanson

Uxin

Top 5 CDRs Gainers/Losers (>100M) (4.8)

ZLAB

OPRA

BEKE

MVST

CSIQ

Adagene(ADAG) rose 2.55%, with a trading turnover 1.9 Million USD, and a year-to-date rose 134.4%. Zai Lab(ZLAB) rose 2.44%, with a trading turnover 9.8 Million USD, and a year-to-date rose 19%. GigaCloud Tech(GCT) fell 9.97%, with a trading turnover 50.1 Million USD, and a year-to-date rose 4.4%. Microvast(MVST) fell 6.88%, with a trading turnover 3.4 Million USD, and a year-to-date fell 46.8%.

- The Nasdaq Composite Index increased by 0.1%, with a year-to-date decline of 5.3%.  
- The S&P 500 Index rose by 0.08% and has dropped 3.3% since the beginning of the year, while the Dow Jones Index fell by 0.18%, with a year-to-date decrease of 3.1%.  
- Among notable stocks, Tianyan Medicine (ADAG) rose by 2.55% year-to-date, and Microvast (MVST) declined by 6.88%, reflecting a significant drop of 46.8% this year.

Zai Lab

Opera

Silvercorp Met

Microvast

LexinFintech

Canadian Solar

Top 5 CDRs Gainers/Losers (>100M) (4.7)

RERE

HUYA

Microvast(MVST) rose 10.34%, with a trading turnover 5.2 Million USD, and a year-to-date fell 42.9%. Adagene(ADAG) rose 8.27%, with a trading turnover 2.0 Million USD, and a year-to-date rose 128.6%. HUYA(HUYA) fell 5.28%, with a trading turnover 2.0 Million USD, and a year-to-date rose 12.2%. Connect Biopharma(CNTB) fell 4.35%, with a trading turnover 1.2 Million USD, and a year-to-date rose 1.4%.

- The Nasdaq Composite Index increased by 0.54%, with a year-to-date decline of 5.4%.  
- The S&P 500 rose by 0.44%, while the Dow Jones Index climbed by 0.36%, both showing year-to-date losses of 3.4% and 2.9%, respectively.  
- Notable stock movements included Microvast (MVST), up 10.34%, and Tianyan Pharmaceuticals (ADAG), up 8.27%, while Huya (HUYA) and Concord Biopharma (CNTB) experienced declines of 5.28% and 4.35%, respectively.

EHang

ATRenew

iQIYI

Jinkosolar

Top 5 CDRs Gainers/Losers (>100M) (4.6)

VNET

Connect Biopharma(CNTB) rose 9.93%, with a trading turnover 2.5 Million USD, and a year-to-date rose 6%. Zhihu(ZH) rose 7.83%, with a trading turnover 1.2 Million USD, and a year-to-date fell 7.6%. Adagene(ADAG) fell 13.45%, with a trading turnover 5.2 Million USD, and a year-to-date rose 111.1%. ATRenew(RERE) fell 5.56%, with a trading turnover 4.4 Million USD, and a year-to-date fell 16.6%.

- The Nasdaq Composite Index rose by 0.18%, with a year-to-date decline of 5.9%.  
- The S&P 500 Index increased by 0.11%, down 3.8% for the year, while the Dow Jones Index fell by 0.13%, down 3.2% year-to-date.  
- Notable stock movements include Conduit BioPharma rising 9.93%, Zhihu increasing by 7.83%, and Tiangang Pharmaceutical decreasing by 13.45%.

Zhihu

Vnet

Top 5 CDRs Gainers/Losers (>100M) (4.2)

Adagene(ADAG.US)

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types | ADAG Stock News

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts

Top 5 CDRs Gainers/Losers (>100M) (4.9)

Analysts Offer Predictions for Adagene FY2026 Earnings

Top 5 CDRs Gainers/Losers (>100M) (4.8)

Top 5 CDRs Gainers/Losers (>100M) (4.7)

Top 5 CDRs Gainers/Losers (>100M) (4.6)

Top 5 CDRs Gainers/Losers (>100M) (4.2)